the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Ovary/Fallopian Tube/Primary Peritoneal Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB16-1770 Moroney, John GOG Partners 3015: A Phase III, Multicenter, Randomized, Placebo- Controlled Study of Atezolizumab Versus Placebo in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III/IV Ovarian, Fallopian tube, or Primary Peritoneal Cancer Details
CIRB17-0986 Moroney, John NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab (IND # ) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer—Safety Lead-in Portion Details
Phase II
Study No PI Title
IRB17-0627 Moroney, John A Phase II Open- Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer Details
IRB17-0114 Moroney, John A Phase II Randomized Study: Outcomes after Secondary Cytoreductive Surgery with or without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by Systemic Combination Chemotherapy for Recurrent Platinum- Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Details
CIRB17-0986 Moroney, John NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab (IND # ) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer—Safety Lead-in Portion Details
IRB16-1368 Fleming, Gini An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer Details
CIRB16-1022 Moroney, John NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Details
IRB16-0606 Romero, Iris Stand Up To Cancer: WISP Trial (Women Choosing Surgical Prevention) Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
10-726-A Moroney, John GOG 264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Details
Phase I
Study No PI Title
IRB18-0228 Fleming, Gini A Phase 1b Trial of Hu5F9-G4 in Combination with Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naïve Ovarian Cancer Patients Who Progress within 6 Months of Prior Platinum Chemotherapy Details
IRB17-1396 Fleming, Gini An Open-Label, Phase 1 Study of SC-004 in Subjects with Advanced Solid Cancers Details
CIRB16-1022 Moroney, John NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1130 Chmura, Steven Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .